TReatment of Pulmonary Hypertension Group II Study

Inclusion Criteria: * Written informed consent to participate in the study obtained from the patient, according to local regulations, prior to initiation of any study mandated procedure. * Male or female, ≥ 18 years of age at the time of screening * Patient with known pulmonary hypertension (PH) due to left heart disease (WHO Group II) diagnosed as either HFpEF or HFrEF at chronic state receiving stable guideline directed medical therapy. * Combined post-capillary and precapillary pulmonary hypertension diagnosis confirmed by hemodynamic evaluation performed prior to screening or during baseline (Eligibility II visit) procedure * Patient with a current diagnosis of NYHA functional class II/III * Patient with eGFR levels of ≥ 30 ml/min/1.73m2or serum creatinine levels of ˂ 150μmol/l Exclusion Criteria: * Pregnant women or women planning a pregnancy within 12 months of study enrolment * Patient with significant co-morbid condition(s) which, at the discretion of the PI, are deemed to prohibit study entry * Patient with life expectancy of less than a year * Concurrent enrollment in another device or drug trial except for observational studies (unless specifically approved by the sponsor) * Patient with pulmonary artery anatomy that precludes treatment * Patient with moderate to severe pulmonary artery stenosis * Patient with any pulmonary artery aneurysm * Patient who has experienced a myocardial infarction, unstable angina pectoris, or a cerebrovascular accident in the previous 6 months * Patient experiencing a current episode of acute decompensated heart failure * Patient who has cardiac pacemakers/ICD/CRT-D that were implanted fewer than three months prior to enrolment. Patient who has implantable Cardiomems device, neurostimulators or drug infusion devices, regardless of implant date.